More From Peter Neil
What Do Analysts Expect for Celanese’s 2Q16 Net Profit Margins?
Analysts expect Celanese’s (CE) net profit margin to be ~16% for 2Q16. This compares to 16.6% in 2Q15 and 18.7% in 1Q16.
Wall Street’s Views and Recommendations for PPG Industries
The number of analysts covering PPG Industries (PPG) has risen from 21 to 22. About 55.0% of them have recommended a “buy” for the stock.
Why Is Deere Trading at a Discount to Caterpillar?
As of December 30, 2016, Deere (DE) was trading at a one-year forward PE multiple of 22.6x compared to Caterpillar’s (CAT) of 30.6x.
AbbVie, Lead Performer of the Pharmaceutical Subgroup
AbbVie (ABBV) rose 18.3% for the week ended October 30, 2015, and closed at $59.55. The stock went up on good 3Q15 earnings.
Olin Surged Ahead in August: Here’s Why
Olin Corporation (OLN) turned out to be one of the best performers among the specialty segments in August.
Why Did Dow’s Consumer Solutions Segment’s Revenue Rise in 2Q16?
The Consumer Solutions segment is Dow Chemical’s lowest revenue generator. In 2Q16, the segment reported revenue of $1.3 billion.
Agios Announces Data from Phase 2 Study of PK Deficiency
Agios Pharmaceuticals was one of the top performers among the small-cap segment within the iShares Nasdaq Biotechnology ETF (IBB) on June 13, 2016.
In 2014, prescription pharmaceuticals generated revenue of $542.84 million, and consumer health generated revenue of $50.23 million— 91.5% and 8.5% of total revenue, respectively.
Celanese Increases Product Prices, Stock Gains Momentum
On May 18, Celanese (CE) announced price hikes for several of its products. The price increase will be effective from June 1.
How Honeywell’s Home & Building Technologies Did in Q2 2018
Honeywell International’s (HON) HBT (Home & Building Technologies) segment is its third-largest revenue contributor.
3M’s Dividend Yield on a (Slow) Sliding Path
As of December 6, 2017, 3M’s (MMM) dividend yield is ~2%, the lowest in the past four years.
W.R. Grace Signs a Spree of New Contracts
On November 27 and 28, 2017, W.R. Grace (GRA) signed a spree of new contracts for its Unipol license.
XBI Recovers from Its Slump
The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.
Biogen Stock Fell for the Week Ending July 24
For the week ending July 24, 2015, Biogen (BIIB) stock fell by -25.86%. The stock fell based on the downward revision of its 2015 revenue.
Why Did LyondellBasell’s 3Q16 Earnings Miss Estimates?
LyondellBasell (LYB) reported adjusted EPS (earnings per share) of $2.31 in 3Q16 compared to $2.80 in 3Q15, implying a fall of 17.5%.
Benchmark Indexes Continue to Outperform IBB and XBI
The iShares NASDAQ Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI) provide investors with an opportunity to hold a basket of stocks from different subindustries from the biotech sector.
How RPM International’s Valuation Compares
Forward price-to-earnings ratio Previously, we discussed analysts’ views on RPM International (RPM). In this part, we’ll compare RPM’s forward PE (price-to-earnings) ratio with peers’. As of December 20, 2017, RPM’s one-year forward PE ratio stood at 17.5x, while peer PPG Industries (PPG) had a PE ratio of 17.6x. Forward PE ratios consider a company’s estimated EPS (earnings […]
A Quick Look at a Few Chemical Companies in 2016
In this series, we’ll take a look at the performances of a few top chemical companies and how the policies of Trump and Clinton could impact those companies.
How HON’s Home and Building Technologies Revenue Trended in 1Q17
Honeywell’s (HON) Home and Building Technologies (or HBT) segment is a new segment that began reporting in 3Q16.
Honeywell Stock since First-Quarter Earnings
Honeywell (HON) is set to announce its Q2 2018 earnings on July 20 before the market opens. Since Q1, the stock has risen 2.4%.
What Drove 3M’s Electronics and Energy Segment’s Revenue in 3Q17
3M’s (MMM) Electronics and Energy segment contributed a revenue share of 17.30% in 3Q17, compared to a revenue share of 16.80% in 3Q16—an increase of 0.50 percentage points on a year-over-year basis.
DE’s Construction and Forestry Segment Reports Expanded Q2 Margin
In the second quarter of fiscal 2019, Deere’s (DE) Construction and Forestry segment reported revenue of $2.99 billion.
Can Deere Stock Continue Its Recovery?
So far in 2018, Deere (DE) has underperformed the broader market S&P 500 (SPY).
Albemarle’s Dividend to Shareholders of Record on June 15
On May 11, 2017, Albemarle (ALB) announced that its quarterly dividend is $0.32 per outstanding share.
Wall Street Analysts’ Views on Praxair ahead of 4Q17 Earnings
Of the 20 analysts currently tracking Praxair, 65% of them have recommended a “buy,” and 30% have recommended a “hold.”
ITW’s Short Interest Is at Its Highest Point: What Could It Mean?
In the latest short interest report, the data indicated that Illinois Tool Works’ short interest was at its highest point of 2018.
Axalta’s 4Q16 Adjusted EPS Manages to Meet Expectations
Axalta Coating Systems (AXTA) reported adjusted EPS (earnings per share) of $0.29 for 4Q16 and managed to meet analysts’ expectation of $0.29.
Why Are Analysts Expecting Honeywell’s EPS to Rise in 4Q16?
As of January 20, 2017, Wall Street analysts expect Honeywell (HON) to post adjusted EPS (earnings per share) of $1.74 in 4Q16.
A Look at IFF’s Second-Quarter Dividend
On July 6, International Flavors & Fragrances (IFF) is set to pay its Q2 2018 cash dividend to common equity shareholders as of June 25.
IBB Falls as Energy Sector Negatively Influences the Market
The iShares Nasdaq Biotechnology ETF (IBB) fell by 2.3% and closed at $324.28, 5% lower than its 100-day moving average price of $341.38.
How Much Upside Do Analysts See for Honeywell?
For Honeywell, 79% of the analysts recommended a “buy,” 21% recommended a “hold,” and none of the analysts recommended a “sell” as of September 6.
Dow Chemical and Sadara Announce Start-Up of Mixed Feed Cracker
On August 29, 2016, Sadara Chemical (SADARA), a joint venture of Dow Chemical (DOW), and Saudi Aramco announced the start-up of its mixed feed cracker.
Why Analysts Are Expecting PPG Industries’ Revenues to Fall in 3Q17
As of October 10, analysts expect PPG Industries (PPG) to post revenues of $3.75 billion in 3Q17, which would be a decline of 1.1% over the previous year.
Grifols and Myriad Traded above the 100-Day Moving Averages
Grifols (GRFS) only fell by 0.34%. It bucked the trend. There were talks that Moody’s upgraded the ratings from “negative” to “stable.”
Analyzing DuPont’s Stock Performance in 2017
With DuPont stock continuing to rise, it’s trading 8.1% above its 100-day moving average of $72.10. The movement indicates the stock’s upward trend.
Stanley Black & Decker Had a Stellar Performance
So far, Stanley Black & Decker (SWK) has given investors good returns among its industrial peers. As of June 5, Stanley Black & Decker has risen 20.70%.
Can 3M Beat Analysts’ Earnings Estimates in 4Q17?
3M (MMM) is expected to post earnings per share (or EPS) of $2.01 in 4Q17, an increase of 6.9% over 4Q16.
XBI Rises in Contrast to a Flat Market
XBI closed at $68.65 on November 17, 2015. Out of XBI’s 101 holdings, 70 stocks ended with positive returns, while 31 stocks ended in the red.
RPM International Reports Strong Revenue Growth in Fiscal 1Q18
RPM International (RPM) reported record first-quarter revenue in fiscal 1Q18.
Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings
Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.
Incyte and Neurocrine Trade above 100-Day Moving Averages
On September 4, 2015, Incyte (INCY) closed trading at $115.88 and continued to trade above 20-day, 50-day, and 100-day moving averages. The stock outperformed the IBB.
Why IFF’s Fragrances Segment’s Profit Fell in 3Q17
The Fragrances segment of International Flavors and Fragrances (IFF) contributes the most to IFF’s overall revenue.
How Are IBB’s American Depositary Receipts Performing?
The ADRs of the iShares Nasdaq Biotechnology ETF (IBB) had negative returns of 1% for the week ended December 4, 2015. IBB provides good exposure to international biotech stocks.
Analyzing XLV’s Trend on Different Moving Averages
On June 14, XLV closed at $71.32. It was trading above its 20-day, 50-day, and 100-day moving averages. XLV’s 20-day moving average was $71.05.
Analyzing IBB’s Moving Averages
As of June 13, 33% of IBB’s stocks were trading above their 20-day moving averages and 43% were trading above their 50-day moving averages.
Why Analysts Think PPG Industries’ 3Q Net Profit Margin Fell
As of October 11, 2016, Wall Street analysts are expecting PPG Industries (PPG) to post a net profit margin of 10.9%.
Ultragenyx Woos Investors with Good Returns in Mid-Cap Space
Ultragenyx Pharmaceutical (RARE) rebounded on December 14, 2015, after falling for four consecutive days. The stock rose 3.8% and was the top performer among the mid-cap stocks that day.
How Are Analysts Rating Dow Chemical ahead of 2Q16 Earnings?
As of July 15, 2016, Dow Chemical’s (DOW) consensus 12-month target price is $58.70. That indicates a return potential of 12.8% from its closing price of $52.06 on July 15.
Reviewing Albemarle’s Stock Performance in 2017
In 2017, Albemarle (ALB) stock made solid gains, rising 49.2% year-to-date. ALB outperformed the SPDR S&P 500 ETF (SPY), which returned 19.6% for the year.
IBB’s American Depository Receipts Outperformed on October 15
The iShares Nasdaq Biotechnology ETF (IBB) gives investors exposure to the international market by investing in ADRs (American depository receipts).
Honeywell’s Short Interest Continues to Stay under 1%
The latest report on September 28 suggests that Honeywell’s short interest remained under 1% of the outstanding shares.
IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status
In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.
The Facts on 3M’s 3Q17 Dividend
On September 12, 3M will pay a dividend of ~$1.18 per share. Investors holding the stock on or before the record date of August 25, 2017, are eligible.
XLV Was Trading Higher after Paying Dividends
The Health Care Select Sector ETF (XLV) rose by 1.1% and closed at $72.38 on December 23. XLV is trading well above its 20-day, 50-day, and 100-day moving averages.
How Wall Street Analysts Rate LyondellBasell ahead of 1Q18 Earnings
The analyst consensus target price for LyondellBasell is $116.82, implying a return potential of 8.5% over the closing price of $107.68 as of April 20, 2018.
What’s the Latest Street View of APD?
As of June 19, of the 20 analysts actively tracking APD stock, 60% had recommended a “buy,” while 30% of the analysts had recommended a “hold.”
Innovative Industrial Properties Declared Q1 Dividend
On March 12, Innovative Industrial Properties’ board declared its first-quarter dividend. The company declared a dividend of $0.45 per share.
Will PPG Industries’ Glass Segment Cease to Exist in 3Q16?
In 2Q16, PPG Industries’ Glass segment contributed ~7% of total revenue, reporting revenue of $282 million in 2Q16, as compared to $279 million in 2Q15.
Horizon Rose and Outperformed IBB’s Mid-Cap Stocks
Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.
Caterpillar: Is Debt Servicing a Big Issue?
Caterpillar has been generating strong free cash flows. In the past five years, Caterpillar has generated an average free cash flow of ~$4.0 billion per year.
3M: Why Are Analysts Cautious?
Analysts’ consensus on 3M indicates a target price of $211.50, which implies a marginal gain of 0.5% over the closing price as of October 9.
International Flavors & Fragrances to Raise $500 Million
On May 15, 2017, International Flavors & Fragrances (IFF) announced its intention to raise $500.0 million in senior notes due in 2047.
Why LYB’s Olefins and Polyolefins – EAI Revenue Fell in 2Q16
In 2Q16, LyondellBasell’s (LYB) Olefins & Polyolefins – Europe, Asia, and International (or EAI) segment reported revenue of $2.7 billion.
XBI’s Large Caps: BioMarin Gives Update on Gene Therapy Study
The large-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 0.3% on April 20, 2016. Large-cap stocks account for 19.3% of XBI’s portfolio.
Westlake Chemical’s Valuation: Still Better Than Peers
As of December 4, 2017, Westlake Chemical’s (WLK) one-year forward PE (price-to-earnings) multiple is 15.10x.
What Are Analysts’ Recommendations for DuPont?
Analysts’ consensus indicates a 12-month target price for DuPont at $78.10—a return potential of 5.5% from its closing price of $74.03 on January 11.
Did IFF’s 3Q16 Results Hurt Its Stock Price?
International Flavors and Fragrances’ (IFF) performance from November 1, 2016, to December 23, 2016, wasn’t pleasant. Let’s take a look at its dividend, valuations, and more.
Praxair to Supply Gases for EverDisplay Optronics in China
On January 22, 2018, Praxair (PX) announced that it has entered a long-term contract with Everdisplay Optronics (EDO), a China-based producer of 4.5 generation AMOLED displays.
Express Scripts Trades Above Its 100-Day Moving Average
Express Scripts Holdings rose 0.4%. The company was in the news on November 10 when it announced that it would remove Linden Care Pharmacy from its network.
SPDR S&P Biotech ETF (XBI) Had a Mixed Day on October 8
The SPDR S&P Biotech ETF (XBI) had a mixed day on October 8, 2015. Of the 101 holdings, 32 stocks ended up in green, and 69 stocks ended up in red. But overall, XBI fell 1.0% for the day.
XBI Moving Averages Are on the Rise
For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.
Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks
Biogen rose 1% on November 25. It closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. It passed the 20-day moving average.
Seattle Genetics Leads XBI Mid-Cap Stocks
Seattle Genetics (SGEN) rose 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.
Incyte Guidance on Jakafi Sends Stock High
On May 23, 2016, Incyte (INCY) was the biggest gainer among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) with a gain of 3.9%.
XBI’s Mid Caps: Ionis Gives Update on Nusinersen Phase 2 Study
The mid-cap stocks of the SPDR S&P Biotech ETF (XBI) rose 1% on April 20, 2016. Within XBI, Ionis Pharmaceuticals’ stock closed at $43.62 on the day.
IBB ADRs Outperform Benchmark for August 10–17, 2015
The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.
Analysts Expect More than $10 Billion in Revenue for Honeywell
Honeywell (HON) is announcing its 4Q16 earnings on January 27, 2017.
Celldex Rose on Phase 2 Melanoma Data
On June 6, 2016, Celldex Therapeutics (CLDX) was one of the top gainers in the small-cap segment of IBB. CLDX stock rose after the company announced its Phase 2 melanoma data.
PPG Industries’ Stock Price Is Still Under Pressure Post-3Q16
PPG Industries’ (PPG) stock performance from November 1, 2016, to December 29, 2016, has been very mild, with a return of 1.6%.
BLUE Is IBB’s Worst-Performing Small-Cap on Disappointing Data
On December 7, 2015, bluebird bio (BLUE) fell 37.6%. The stock fell after it announced disappointing clinical data for its BB305 treatment.
Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings
Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.
LyondellBasell Announces New Share Repurchase Program
On May 24, 2017, LyondellBasell’s (LYB) board authorized a new share repurchase program. It can repurchase up to 10% of its outstanding shares over the next 18 months.
PPG Industries Will Acquire The Crown Group
On July 20, 2017, PPG Industries (PPG) announced that it has entered into a definitive agreement to acquire The Crown Group.
How Does XBI Compare to Its 100-Day Moving Average?
The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.
Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally
Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.
Why Are Analysts Expecting Axalta’s Revenue to Rise in 4Q16?
Analysts are expecting Axalta (AXTA) to post revenue of $1.02 billion in 4Q16. That’s a 1.2% rise year-over-year compared to $1.01 billion in 4Q15.
IMMU and ACRX Outperform in the Biotech Downdraft
Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. The stock closed at $2.08.
Honeywell’s Performance Materials and Technologies: Why It Fell
Honeywell’s (HON) Performance Materials and Technologies (or PMT) segment accounted for 22.2% of HON’s total revenue in 2Q17.
Organic Growth Drives Up 3M’s 1Q17 Revenues
The rise in 3M’s revenue was primarily driven by better-than-expected organic growth across all segments, with the exception of the Consumer segment.
How Did Ziopharm Keep XBI from Losing More Ground?
Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.
Alexion Continues to Rise on FDA’s Approval of Kanuma
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
Why Analysts Expect Honeywell’s Revenues to Fall in 2Q17
Honeywell signed an agreement with VietJet Air to supply 98 auxiliary power units to its fleet of 135 Airbus A320s. The deal was valued at $100 million, which includes maintenance services for 12 years.
How Celgene Reacted to Positive Clinical Trials on October 26, 2015
Celgene rose by 2.95% and closed at $123.65, surpassing its 50- and 100-day moving average prices of $118.45 and $121.09.
Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials
Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.
Radius Continued to Fall despite Positive Data on Osteoporosis
Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.
Albemarle Aims to Double Lithium Production in Australia
On March 16, 2017, Albemarle (ALB) announced that it will double its lithium production capacity at its spodumene mine in Greenbushes, Australia.
Quest Gains after Acquisition of Clinical Laboratory Partners
Quest Diagnostics (DGX) gained 2.9% on March 1, 2016, as it announced the completion of Outreach Laboratory
Adeptus Health Leads the Small-Cap Space with 3.6% Gain
Adeptus Health (ADPT) rose by 3.6% on November 10, 2015. The stock rose following its announcement that it had officially opened its first Texas hospital.
Horizon Pharma Appears to Be on an Acquisition Spree
Horizon Pharma (HZNP), after acquiring Vidara Therapeutics on September 19, 2014, completed its second acquisition of Hyperion Therapeutics (HPTX) on May 7, 2015.
Praxair Secures a New Long-Term Contract
Praxair has entered into a long-term agreement to supply oxygen for Fulcrum BioEnergy’s Sierra BioFuels Plant in Storey County, Nevada.